Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

dexmethylphenidate

Adjunctive therapy

Brands: FOCALIN, FOCALIN XR

Published 2026-02-13 · Last reviewed 2026-02-20 · 5 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.·Half-life: Single-dose mean 3 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.
Half-life: Single-dose mean 3 h
LAI available: No

Quick answers

What is dexmethylphenidate?: Dexmethylphenidate (brands Focalin and Focalin XR) is the d‑enantiomer of methylphenidate and is used as a first-line stimulant option for ADHD. In practice, it often achieves similar clinical effect at lower milligram doses than racemic methylphenidate.
What is FOCALIN?: FOCALIN is a brand name for dexmethylphenidate (other brands: FOCALIN XR).
What is FOCALIN (dexmethylphenidate) used for?: Label indications include: Attention-deficit/hyperactivity disorder (ADHD).
What drug class is FOCALIN (dexmethylphenidate)?: CNS Stimulant.
What is the mechanism of action of FOCALIN (dexmethylphenidate)?: CNS stimulant; d-enantiomer of methylphenidate that inhibits dopamine and norepinephrine reuptake (DAT/NET).
What strengths does FOCALIN (dexmethylphenidate) come in?: Immediate-release tablets (often dosed twice daily).
What is the maximum recommended dose of FOCALIN (dexmethylphenidate)?: Maximum recommended dose depends on the specific product; labels specify maximums, and escalation beyond typical ranges usually prompts reassessment of diagnosis, adherence, and sleep.

General information

Dexmethylphenidate is the d‑enantiomer of methylphenidate and is used as a first-line stimulant option for ADHD. Clinically it often achieves similar symptom control at lower milligram doses than racemic methylphenidate.

Immediate-release products emphasize flexibility and short duration, while extended-release products support once-daily morning dosing with a smoother day-long effect. Matching duration to the patient’s impairment window is central to success.

In patients with serious mental illness (or vulnerability to mania or psychosis), stimulants can worsen insomnia, anxiety, irritability, or psychotic symptoms. Diagnosis confirmation, primary illness stabilization, conservative titration, and close follow-up are common strategies in higher-risk settings.

The dexmethylphenidate compare view, dexmethylphenidate evidence feed, and dexmethylphenidate print page can support safe-use counseling.

U.S. approvals

Attention-deficit/hyperactivity disorder (ADHD)

Formulations & strengths

Immediate-release tablets (often dosed twice daily).
Extended-release capsules (typically once daily in the morning).

Generic availability

Widely available generically (IR and ER).

Dose “success” depends on coverage, not peak stimulation. The most common problems are late-day dosing that disrupts sleep, inadequate duration for the work/school day, and titration that ignores appetite loss and anxiety. Dose conversions across stimulant products are treated as approximate, and symptoms and function are re-evaluated after each change.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Inhibits dopamine and norepinephrine reuptake transporters (DAT/NET), increasing catecholamine signaling in circuits relevant to attention, working memory, and impulse control.

Clinical benefits can appear quickly; response is often tracked using concrete functional measures (task completion, fewer errors, improved driving attention) rather than subjective energy.

Because it is activating, dexmethylphenidate can worsen insomnia and anxiety when dosing is late or titration is too aggressive.

DAT/NET reuptake inhibition increases dopamine and norepinephrine signaling.
Limited direct serotonergic activity compared with many antidepressants.

Metabolism & pharmacokinetics

Primarily metabolized by carboxylesterase (CES1); not a clinically meaningful CYP substrate.
Short intrinsic half-life; extended-release delivery systems increase duration of effect without substantially changing clearance.
Food and formulation influence onset and peak effects; meal timing can matter when patients report abrupt onset or afternoon “crashes.”

Dosing & administration

Typical initiation is at a low dose with weekly titration based on benefit and tolerability; immediate-release products are commonly BID, while extended-release products are usually once daily in the morning.
Typical daily doses are product- and age-dependent; labeled maximums vary by formulation (often about 20 mg/day for IR and 40 mg/day for ER).
Late-day dosing can worsen insomnia; when evening rebound appears, adjusting duration/timing is often tried before adding sedating medications.
When switching from methylphenidate, expect lower milligram dosing needs but treat conversions as approximate; coverage and side effects are commonly monitored closely during the first 1–2 weeks.
If benefit is minimal at reasonable doses, clinicians often reassess ADHD diagnosis, sleep disorders, comorbid anxiety/depression, and substance use rather than escalating indefinitely.

Monitoring & labs

Baseline and periodic blood pressure and heart rate (more often during titration).
Appetite and weight/BMI, with nutrition and meal timing revisited if weight loss occurs.
Sleep onset and total sleep time; timing/formulation adjustments are often tried before adding sedatives.
Anxiety, agitation, mood elevation, or hallucinations; emergent symptoms generally prompt reassessment and discontinuation when appropriate.
Misuse/diversion risk at follow-up; safe storage counseling is commonly documented.

Sources: DailyMed label(s); guideline statements; network meta-analysis context.

Adverse effects

FDA boxed warnings

Boxed warning: CNS stimulants have a high potential for abuse and dependence; misuse risk is typically assessed before prescribing, and diversion and escalating use are monitored.

Common side effects (≥10%)

Appetite suppression / weight loss: Common early; weight/BMI is commonly tracked and dose timing, nutrition strategies, or formulation changes can help.
Insomnia: Often reflects late dosing or rebound; earlier dosing or formulation changes are common strategies.
Increased heart rate / blood pressure: Vitals are often monitored during titration, especially with cardiovascular disease.
Anxiety / irritability: Can emerge with rapid titration; slower titration and reassessing comorbid anxiety/bipolar risk are common strategies.
Headache / GI upset: Often improves with time or food; slower titration is sometimes used.

Other notable effects

Psychiatric symptoms can include agitation, mood elevation, or hallucinations; emergent mania or psychosis symptoms generally prompt reassessment and discontinuation when appropriate.
Tic worsening can occur; differentiate medication effects from anxiety and restlessness.
Peripheral vasculopathy (Raynaud-like symptoms) and rare priapism have been reported; counseling often covers urgent symptoms.

Interactions

Contraindicated with MAO inhibitors; adequate washout is required.
Additive sympathomimetic effects can occur with decongestants and other stimulants; vital signs and anxiety symptoms are commonly monitored.
Alcohol can worsen impairment and may alter release characteristics of some extended-release products.

Other useful information

Titration is often anchored to function (work output, fewer errors, improved driving attention); reassessment after each dose change is typical.
Sleep disorders are commonly screened for and treated because they can masquerade as inattention.
In patients with bipolar spectrum illness or psychosis vulnerability, primary illness stabilization is often prioritized and activation is monitored closely.
Diversion prevention counseling often includes locked storage, not sharing, and clear refill policies.

References

Related hubs:SMI toolkit·Support resources